The DEA and HHS announced a third temporary extension of COVID-19 telemedicine flexibilities for prescribing controlled medications, preventing patient medication access issues until December 31, 2025. The agencies are developing final rules for virtual prescribing to ensure public health and safety while addressing concerns over access barriers post-pandemic. They continue to consider feedback from stakeholders.
The True Cost of Focusing on Cost Instead of Cost-Effectiveness
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is
